スペインのがん疼痛管理市場予測　2024-2032年

Report Overview

KEY FINDINGS
The Spain cancer pain management market is projected to grow with a CAGR of 5.32% during the forecast period 2024-2032.

スペインのがん疼痛管理市場は、2024年から2032年の予測期間中に5.32%のCAGRで成長すると予測されています。

MARKET INSIGHTS
REDECAN’s 2024 cancer incidence estimates for Spain project a total of 286,664 new cases, with 161,678 in males and 124,986 in females. Among men, the most prevalent cancers are prostate (30,316 cases), lung (22,483 cases), urinary bladder (18,247 cases), colon (17,793 cases), and rectum (9,216 cases). For women, breast cancer leads with 36,395 cases, followed by colon (11,855 cases), lung (10,285 cases), uterine body (7,305 cases), and rectum (5,430 cases).
Cancer incidence in Spain varies significantly by age group. 15,938 new cases are expected in individuals aged 0 to 44 (5.6% of total cancers), 99,391 cases in those aged 45 to 64 (34.7% of total cancers), and 171,335 cases in those aged 65 and older (59.8% of total cancers). This growing cancer prevalence highlights the urgent need for advanced pain management strategies. Healthcare providers are increasingly focusing on improving cancer patient’s quality of life through comprehensive pain management solutions.
As of January 2023, Spain’s elderly population aged over 65 numbered 9.68 million, continuing a growth trend since 2002, when this population increased by over two million. Currently, people over 65 constitute nearly one-fifth of Spain’s total population. The significant rise in cancer cases, particularly among the elderly, emphasizes the critical need for effective pain management solutions. The increasing number of elderly individuals who are more susceptible to cancer drives the demand for specialized cancer pain management services tailored to their specific needs.
Personalized medicine, which tailors treatment to individual patient characteristics such as genetic profile, can enhance the effectiveness and reduce the side effects of cancer pain therapies. This approach is particularly relevant as Spain experiences a rise in cancer cases, necessitating more targeted and efficient cancer pain treatment strategies. Personalized therapies provide tailored pain relief, improving the quality of life for cancer patients and addressing diverse pain management needs more precisely than traditional one-size-fits-all treatments.

REPORT SYNOPSIS

SEGMENTATION ANALYSIS
The report on the Spain cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:
• Opioids
• Morphine
• Fentanyl
• Other Morphines
• Non-Opioids
• Acetaminophen
• Non-Steroidal Anti-Inflammatory drugs (NSAIDS)
• Nerve Blockers
Market by Disease Indication:
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Other Disease Indications
Inkwood Research’s report on the Spain cancer pain management market provides in-depth insights as well as the market’s segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis.

COMPETITIVE ANALYSIS
Key players operating in the Spain cancer pain management market include Daiichi Sankyo Company Ltd, Shionogi & Co Ltd, Pfizer, Teva Pharmaceutical Industries Limited, Mundipharma International, Grünenthal Pharma GmbH & Co KG.
Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan, is a holding company that manufactures and sells pharmaceuticals. The company focuses on various therapeutic areas, including infectious diseases, cardiovascular diseases, bone and joint diseases, and contrast media. Operating across Asia, Europe, and the Americas, Daiichi Sankyo offers its products and services in over 20 countries worldwide.

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT — SPAIN
2.3. COUNTRY ANALYSIS — SPAIN
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.5.1. IMPACT OF COVID-19 ON THE SPAIN CANCER PAIN MANAGEMENT MARKET
2.6. MAJOR MARKET FINDINGS
2.6.1. INNOVATIONS IN PALLIATIVE CARE
2.6.2. SURGE IN PERSONALIZED MEDICINE APPROACHES
2.6.3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING PREVALENCE OF CANCER IN SPAIN
3.1.2. SURGE IN GERIATRIC POPULATION
3.1.3. ADVANCED HEALTHCARE INFRASTRUCTURE
3.2. KEY RESTRAINTS
3.2.1. REGULATORY CHALLENGES AND APPROVAL DELAYS
3.2.2. HIGH COST OF TREATMENT
3.2.3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN SPAIN
4.1.2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
4.1.3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES
4.2. PESTLE ANALYSIS
4.2.1. POLITICAL
4.2.2. ECONOMICAL
4.2.3. SOCIAL
4.2.4. TECHNOLOGICAL
4.2.5. LEGAL
4.2.6. ENVIRONMENTAL
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTIONS
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING — SPAIN
4.5. VALUE CHAIN ANALYSIS
4.5.1. RESEARCH & DEVELOPMENT
4.5.2. REGULATORY APPROVAL
4.5.3. MANUFACTURING
4.5.4. DISTRIBUTION
4.5.5. END-USERS
5. MARKET BY DRUG TYPE
5.1. OPIOIDS
5.2. MORPHINE
5.2.1. FENTANYL
5.2.2. OTHER MORPHINES
5.3. NON-OPIOIDS
5.4. ACETAMINOPHEN
5.5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6. NERVE BLOCKERS
6. MARKET BY DISEASE INDICATION
6.1. LUNG CANCER
6.2. COLORECTAL CANCER
6.3. BREAST CANCER
6.4. PROSTATE CANCER
6.5. BLOOD CANCER
6.6. OTHER DISEASE INDICATIONS
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. DAIICHI SANKYO COMPANY LIMITED
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCTS
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. SHIONOGI & CO LTD
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCTS
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. PFIZER
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCTS
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. TEVA PHARMACEUTICAL INDUSTRIES
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCTS
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. MUNDIPHARMA INTERNATIONAL
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCTS
7.2.5.3. STRENGTHS & CHALLENGES
7.2.6. GRÜNENTHAL PHARMA GMBH & CO KG
7.2.6.1. COMPANY OVERVIEW
7.2.6.2. PRODUCTS
7.2.6.3. STRENGTHS & CHALLENGES

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – CANCER PAIN MANAGEMENT
TABLE 2: SPAIN CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: SPAIN CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: SPAIN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: SPAIN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: SPAIN CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: SPAIN CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 8: LIST OF MERGERS & ACQUISITIONS
TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

List of Figures

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING — SPAIN
FIGURE 4: VALUE CHAIN ANALYSIS
FIGURE 5: SPAIN CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2023
FIGURE 6: SPAIN CANCER PAIN MANAGEMENT MARKET, BY OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 7: SPAIN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, 2024-2032 (IN $ MILLION)
FIGURE 8: SPAIN CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY MORPHINE, IN 2023
FIGURE 9: SPAIN CANCER PAIN MANAGEMENT MARKET, BY FENTANYL, 2024-2032 (IN $ MILLION)
FIGURE 10: SPAIN CANCER PAIN MANAGEMENT MARKET, BY OTHER MORPHINES, 2024-2032 (IN $ MILLION)
FIGURE 11: SPAIN CANCER PAIN MANAGEMENT MARKET, BY NON-OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 12: SPAIN CANCER PAIN MANAGEMENT MARKET, BY ACETAMINOPHEN, 2024-2032 (IN $ MILLION)
FIGURE 13: SPAIN CANCER PAIN MANAGEMENT MARKET, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2024-2032 (IN $ MILLION)
FIGURE 14: SPAIN CANCER PAIN MANAGEMENT MARKET, BY NERVE BLOCKERS, 2024-2032 (IN $ MILLION)
FIGURE 15: SPAIN CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DISEASE INDICATION, IN 2023
FIGURE 16: SPAIN CANCER PAIN MANAGEMENT MARKET, BY LUNG CANCER, 2024-2032 (IN $ MILLION)
FIGURE 17: SPAIN CANCER PAIN MANAGEMENT MARKET, BY COLORECTAL CANCER, 2024-2032 (IN $ MILLION)
FIGURE 18: SPAIN CANCER PAIN MANAGEMENT MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)
FIGURE 19: SPAIN CANCER PAIN MANAGEMENT MARKET, BY PROSTATE CANCER, 2024-2032 (IN $ MILLION)
FIGURE 20: SPAIN CANCER PAIN MANAGEMENT MARKET, BY BLOOD CANCER, 2024-2032 (IN $ MILLION)
FIGURE 21: SPAIN CANCER PAIN MANAGEMENT MARKET, BY OTHER DISEASE INDICATIONS, 2024-2032 (IN $ MILLION)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧